Physician profile
James E Croley
NPI 1295799849
$1,079.41
in general payments reported to CMS, 2019-2025
14 companies · $107 in 2025
The $107 reported for 2025 was less than what a typical Ophthalmology provider received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $140 · 2020: $131 · 2021: $300 · 2022: $174 · 2023: $87.71 · 2024: $140 · 2025: $107.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $334.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $334.48 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Kala Pharmaceuticals, INC. | $331.23 | 2019-2022 | |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $132.95 | 2019-2021 | |
| Dompe US, INC. | $121.43 | 2024-2025 | Oxervate |
| Bausch & Lomb Americas INC. | $117.96 | 2022-2025 | Miebo, Scoutpro Osmolarity System, Xiidra |
| Mallinckrodt Hospital Products INC. | $95.45 | 2021-2022 | |
| Alcon Vision LLC | $63.46 | 2019-2024 | Clareon, Rocklatan |
| Sight Sciences, INC. | $54.96 | 2023-2025 | Tearcare System, Omni Surgical System, Sion Surgical Instrument |
| Aerie Pharmaceuticals, INC. | $39.16 | 2019-2021 | |
| Rayner Intraocular Lenses Limited | $26.05 | 2024 | Omidria |
| Novartis Pharmaceuticals Corporation | $20.50 | 2021 | |
| Thea Pharma INC. | $19.24 | 2023 | Iyuzeh |
| Abbvie INC. | $19.07 | 2022 | |
| Sun Pharmaceutical Industries INC. | $19.07 | 2021 | |
| Biotissue Holdings INC. | $18.88 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw James Croley listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.